Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study
Cancers · 18.06.2026 · 18 (12) · 1979
DOI: 10.3390/cancers18121979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 18.06.2026. Verfasst von Bahadır Köylü und 59 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Koç University School of Medicine, Istanbul 34010, Türkiye. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: We aimed to evaluate the real-world outcomes of first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer, together with the progression patterns, including the management and outcomes of oligoprogressive disease in the real-world setting.
Methods
Patients who received first-line osimertinib at 33 oncology centers across Türkiye were retrospectively analyzed.
Results
The median (IQR) age of 143 patients was 59.4 (50.9–68.9), 62.9% were female, and 68.5% were non-smokers. The most frequently identified EGFR mutations were exon 19 deletion (64.3%) and exon 21 L858R (28.7%). The median progression-free survival (PFS) was 17.6 months (95% CI 14.6–20.6). Exon 19 deletion subgroup had significantly longer median PFS than exon 21 L858R subgroup (22.0 vs. 11.7 months; HR = 0.40 [95% CI 0.25–0.64]; p < 0.001). Of the patients who experienced disease progression, 51.2% had oligoprogression. Among these, 81.8% received local ablative treatments (LATs) while continuing osimertinib. The median time to osimertinib discontinuation was significantly longer in patients treated with LATs than in those who continued osimertinib without LATs (8.5 vs. 3.0 months; p = 0.001). In the overall cohort, 12- and 24-month overall survival (OS) rates were 93.0% and 82.5%, respectively. The median OS was significantly longer in patients with oligoprogression compared to those with systemic progressive disease (57.7 vs. 36.5 months; p = 0.007). Any-grade and grade ≥ 3 osimertinib-related adverse events occurred in 55.2% and 6.3% of patients, respectively.
Conclusions
This study supports the real-world effectiveness and tolerability of first-line osimertinib. Oligoprogression was associated with longer OS compared with systemic progression, and the integration of LATs in carefully selected patients with oligoprogression may be associated with prolonged osimertinib treatment duration and favorable post-progression outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Koç University School of Medicine, Istanbul 34010, Türkiye.
- Department of Medical Oncology, Başakşehir Çam and Sakura City Hospital, Istanbul 34480, Türkiye.
- Division of Medical Oncology, Department of Internal Medicine, Medipol University School of Medicine, Istanbul 34214, Türkiye.
- Division of Medical Oncology, Department of Internal Medicine, Acibadem University, Istanbul 34752, Türkiye.
- Division of Medical Oncology, Department of Internal Medicine, Uskudar University Faculty of Medicine, Istanbul 34768, Türkiye.
- Department of Medical Oncology, Yeditepe University, Istanbul 34755, Türkiye.
ORCID-Profile: Bahadır Köylü, Harun Muğlu, Serdar Karakaya, Özlem Er, Hasibe Bilge Gür, Duygu Ercan Uzundal, Esra Aşık, Engin Kut, Taha Koray Şahin, Emine Türkmen, Ahmet Bilici, İlhan Hacıbekiroğlu, Atila Yıldırım, Mehmet Ali Nahit Şendur, Ferhat Ekinci, Gamze Gököz Doğu
Zitieren
APA
Köylü, B., Celayir, Ö. M., Muğlu, H., Can, O., Şen, F., Öven, B. B., Demirci, U., Şakalar, T., Karakaya, S., Er, Ö., Ekinci, Ö. B., Sakin, A., Gür, H. B., Karaman, Y., Ercan Uzundal, D., Aşık, E., Pilancı, K. N., Avcı, N., Gürsoy, P., …, & Kılıçkap, S. (2026). Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study. Cancers, 18(12), 1979. https://doi.org/10.3390/cancers18121979
Vancouver
Köylü B, Celayir ÖM, Muğlu H, Can O, Şen F, Öven BB, et al. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study. Cancers. 2026;18(12):1979. doi:10.3390/cancers18121979
BibTeX
@article{Kyl2026,
author = {Köylü, Bahadır and Celayir, Özde Melisa and Muğlu, Harun and Can, Orçun and Şen, Fatma and Öven, Bala Başak and Demirci, Umut and Şakalar, Teoman and Karakaya, Serdar and Er, Özlem and Ekinci, Ömer Burak and Sakin, Abdullah and Gür, Hasibe Bilge and Karaman, Yağmur and Ercan Uzundal, Duygu and Aşık, Esra and Pilancı, Kezban Nur and Avcı, Nilüfer and Gürsoy, Pınar and Kaplan, Muhammet Ali and Menekşe, Serkan and Kut, Engin and Arpacı, Erkan and Kosku, Hakan and Bayram, Selami and Şahin, Taha Koray and Türkmen, Emine and Aykut, Abdurrahman and Ağyol, Yeşim and Özveren, Ahmet and Şahin, Elif and Ateş, Öztürk and Serin Özel, Gamze and Kıkılı, Cevat İlteriş and Kemik, Fatih and Oyan, Başak and Korkmaz, Taner and Demir, Osman Gökhan and Tural, Deniz and Gündüz, Şeyda and Laçin, Şahin and Demir, Nazan and Tunalı, Didem and Bilici, Ahmet and Ölmez, Ömer Fatih and Hacıbekiroğlu, İlhan and Çubukçu, Erdem and Yazıcı, Ozan and Yıldırım, Atila and Bilgin, Burak and Şendur, Mehmet Ali Nahit and Tatlı, Ali Murat and Özdoğan, Mustafa and Aktaş, Burak Yasin and Kanıtez, Metin and Karabulut, Bülent and Ekinci, Ferhat and Bayram, Ertuğrul and Gököz Doğu, Gamze and Kılıçkap, Saadettin},
title = {Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1979},
doi = {10.3390/cancers18121979}
}
EUVIMED